CRUSHMETRIC Group Limited

OFEX:CUSH Stock Report

Market Cap: UK£30.0m

CRUSHMETRIC Group Valuation

Is CUSH undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CUSH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate CUSH's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate CUSH's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for CUSH?

Key metric: As CUSH is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for CUSH. This is calculated by dividing CUSH's market cap by their current revenue.
What is CUSH's PS Ratio?
PS Ratio43.3x
SalesHK$6.88m
Market CapHK$297.84m

Price to Sales Ratio vs Peers

How does CUSH's PS Ratio compare to its peers?

The above table shows the PS ratio for CUSH vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1.6x
TLY Totally
0.2x3.1%UK£15.9m
IDHC Integrated Diagnostics Holdings
2.5x19.1%US$241.8m
KOO Kooth
1.2x9.4%UK£63.5m
GENI GENinCode
2.6xn/aUK£6.7m
CUSH CRUSHMETRIC Group
43.3xn/aUK£30.0m

Price-To-Sales vs Peers: CUSH is expensive based on its Price-To-Sales Ratio (43.3x) compared to the peer average (1.6x).


Price to Sales Ratio vs Industry

How does CUSH's PS Ratio compare vs other companies in the European Healthcare Industry?

4 CompaniesPrice / SalesEstimated GrowthMarket Cap
CUSH 43.3xIndustry Avg. 0.6xNo. of Companies10PS00.40.81.21.62+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: CUSH is expensive based on its Price-To-Sales Ratio (43.3x) compared to the European Healthcare industry average (0.6x).


Price to Sales Ratio vs Fair Ratio

What is CUSH's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CUSH PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio43.3x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate CUSH's Price-To-Sales Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies